The Menstrual Cycle and Type 1 Diabetes, Part 3: Contraception, PCOS, Pregnancy, Menopause

The decisions you make once and the ones that come back

Some of the conversations in this part you will have once: the contraception choice that fits your life and your T1D, the pregnancy planning conversation if and when it comes. Others arrive without warning: the polycystic ovary syndrome diagnosis you did not know to ask about, the perimenopause that arrives a few years earlier than it did for your mother. T1D sits next to all of them, and each one has its own evidence layer.

This part is a tour, not a textbook. It exists to give you the named guidelines, the headline evidence, and the language to take to the team that handles each station, because no single clinic in the UK is set up to handle all four together. Your diabetes team handles the diabetes. Your GP handles the contraception conversation. A specialist diabetes-in-pregnancy team handles pregnancy. A gynaecologist handles PCOS or menopause work. Knowing who to ask, and what to bring, is half the work.

Contraception in T1D, and what the evidence does and does not say

You arrive at the GP appointment ready for the standard contraception conversation. The leaflet is the same one your friend without diabetes was given, and the GP is asking you the same questions. The hesitation, if there is any, is whether the combined oral contraceptive pill will make your glucose run higher, whether the coil is a better idea because of your insulin, whether anyone has actually studied this.

Visser and colleagues (2013, Cochrane Database of Systematic Reviews) reviewed hormonal versus non-hormonal contraceptives in women with T1D and T2D. Four randomised controlled trials met inclusion criteria; no unintended pregnancies were reported. The one trial of good methodological quality (levonorgestrel-releasing intrauterine device versus copper IUD in T1D) showed no significant difference in carbohydrate metabolism. Most regimens left blood glucose stable; only high-dose combined oral contraceptives and the specific combination of 30 micrograms ethinylestradiol plus 75 micrograms gestodene were identified as slightly impairing glucose homeostasis. Lipid metabolism findings were mixed and small in magnitude.

What the Cochrane review does not yet cover: the AID era, the rt-CGM era, and the question of whether a hormonal contraceptive interacts with your specific cycle pattern in a way that needs algorithm-side adjustment. These are real evidence gaps, and the position above is the strongest synthesis we have at present.

In most T1D women, contraception choice can be guided by the same considerations a woman without diabetes would weigh. High-dose combined oral contraceptives are a relative caution flag. If you change a contraceptive, your CGM is the cleanest way to see whether your cycle pattern shifts; two or three cycles of overlay data is enough to read the answer. Bring the question to your GP, and bring the line back to your diabetes team if the new contraceptive shifts your glucose pattern. The team that prescribes the contraceptive is rarely the team that adjusts your insulin, and the conversation has to bridge.

Polycystic ovary syndrome in women with T1D

The diagnosis often comes up sideways. The acne that did not improve when you thought you had grown out of it. The cycle that became irregular three years ago and you assumed was stress. The friend who got the PCOS diagnosis at the same age and asked whether you had been screened. PCOS is more common in women with T1D than in matched controls, and it is under-recognised in routine adult diabetes clinic.

Codner and colleagues (2007, Journal of Clinical Endocrinology and Metabolism) compared women with T1DM against carefully matched healthy controls. Women with T1DM had significantly higher hirsutism (Ferriman-Gallwey score), higher waist-to-hip ratio, and higher polycystic ovary morphology and PCOS prevalence than controls. Within the T1DM cohort, polycystic ovary morphology and PCOS were associated with intensive insulin treatment specifically (three or more daily injections or pump), not with total daily insulin dose, HbA1c, or premenarcheal versus postmenarcheal onset. The authors flagged this as hypothesis-generating; the prevalence finding itself is robust.

The international Teede 2023 PCOS guideline (NHMRC-approved, 39 organisations across 71 countries) reaffirms the doubled lifetime risk of T2D in women with PCOS and recommends an oral glucose tolerance test at diagnosis and at intervals through reproductive life. The guideline focuses on PCOS in the general population, with the T1DM-specific evidence acknowledged as sparse.

If the symptoms (irregular cycles, acne, hirsutism, weight redistribution) sit alongside your T1D and have not been raised at clinic, raise them. The PCOS work-up is gynaecology and endocrinology, not the diabetes team’s, and the referral is straightforward to ask for. Your GP and your diabetes team can both make the gynaecology referral. A clinician with PCOS expertise (specialist endocrinology or reproductive endocrinology) is the right destination. Bring the cycle history, the symptom history, and the question. The conversation that lands is the one that names PCOS as the suspected diagnosis, not the one that asks “is this normal?”.

Pregnancy in T1D, the evidence has changed

The pregnancy chapter of T1D has moved more in the last eight years than in the previous thirty. CGM in pregnancy, hybrid closed-loop in pregnancy, real-world AID outcomes across UK NHS sites: each has landed in a way that changes what the planning conversation can sound like. If you are planning pregnancy, or you are in early pregnancy now, the pathway you are joining is materially better than the one your mother might have walked.

Preconception

The preconception target in NICE NG3 (Diabetes in pregnancy, last updated December 2020) is HbA1c below 6.5 per cent (48 mmol/mol) where achievable without problematic hypoglycaemia, with 5 mg folic acid daily from preconception to twelve weeks gestation. The HbA1c target is tighter than the non-pregnancy target, and the structured preconception clinics that exist in most UK regions are the place where the run-up to conception is supported. If you are using AID before pregnancy, you can carry it into pregnancy. AiDAPT (Lee 2023, NEJM) is the evidence base for the December 2020 NICE NG3 update on real-time CGM in pregnancy and the contemporary case for AID in pregnancy: pregnancy time-in-range improved by 10.5 percentage points versus standard care, equivalent to roughly 2.5 additional hours per day in target range. CRISTAL (Benhalima 2024, MiniMed 780G in pregnancy) is the next pivotal trial in the same space.

Antenatal care

NICE NG3 recommends real-time CGM for all pregnant women with T1D, driven by the CONCEPTT trial (Feig 2017, Lancet): real-time CGM in pregnancy improved HbA1c modestly and reduced large-for-gestational-age, neonatal hypoglycaemia, NICU admission longer than twenty-four hours, and neonatal hospital stay. The pregnancy-specific glycaemic targets are tighter: fasting below 5.3 mmol/L (95 mg/dL), one-hour postprandial below 7.8 mmol/L (140 mg/dL), two-hour postprandial below 6.4 mmol/L (115 mg/dL), avoiding hypoglycaemia below 4 mmol/L (72 mg/dL). Aspirin 75 to 150 mg daily from twelve weeks until birth reduces pre-eclampsia risk in women with T1D. The continuous risk gradient between maternal hyperglycaemia and adverse perinatal outcome at glucose levels well below the conventional diabetes diagnostic threshold was established by HAPO (2008, NEJM); HAPO is the reason pregnancy targets are tighter.

Intrapartum

The UK operational standard during established labour is a maternal capillary plasma glucose target of 4 to 7 mmol/L (72 to 126 mg/dL) (JBDS-IP 12, February 2023). Variable-rate intravenous insulin infusion is recommended for women with T1D in established labour, or for any woman with diabetes whose oral intake is restricted or whose glucose drifts above target. Continuation of pump and CGM during labour is permitted where the woman wishes and the unit is competent. After delivery, insulin requirements drop sharply; immediate dose review is required.

What the UK national audit shows

The National Pregnancy in Diabetes Audit (NHS England, NHS Digital, Diabetes UK, HQIP) tracks the quality of antenatal care and pregnancy outcomes for women with pre-gestational diabetes at provider level. The 2023 dashboard (covering pregnancies that ended between January 2021 and December 2023, published August 2024) is the first NPID release to include CGM uptake data, reflecting the December 2020 NICE NG3 update. The UK provider-level data is the cleanest contemporary snapshot of what real-world pregnancy outcomes look like.

The planning conversation that begins with HbA1c, folic acid, and a CGM referral is the one that opens the door to the best contemporary outcomes. The pathway exists; the team that runs it is the diabetes-in-pregnancy clinic in your region. Your diabetes team is the first conversation. If you are planning, ask for the preconception clinic referral. If you are pregnant now, ask for the joint diabetes-and-obstetric referral and for a CGM if you are not already on one. Bring your data, ask early, ask in writing if the first answer is delayed.

Menopause and T1D, the most under-served station

You spent twenty years adjusting your insulin around your cycle and you assumed the menopause would be the moment the cycle question went away. Some weeks now it does. Other weeks the hot flush at three in the morning is followed by a glucose spike you cannot place, the carb-counted dinner does not work the way it did last year, and the literature you reach for on menopause and T1D thins out. You are not imagining the gap. The gap is real.

Courtney and Owens (2025, Endocrine Connections) is the most current synthesis of menopause in women with T1DM, and the review opens by naming the gap explicitly: the 2013 Cochrane review on hormone replacement therapy in diabetes identified only one small underpowered trial that also included T2DM women; the 2018 EMAS clinical guide on menopause and diabetes (Slopien 2018, Maturitas) makes minimal reference to T1DM; the 2022 Nature Reviews Endocrinology article on menopause and diabetes focuses primarily on T2DM. T1DM women have not been the focus of menopause research, and the practical guidance reflects that thinness.

What the review covers: the age of menopause may be slightly earlier in T1DM than in the general population, with implications for the cardiovascular risk window. Glycaemic control and insulin requirements often shift across the menopause transition; population data are sparse and individual variation is large. T1DM is associated with lower bone mineral density and higher fracture risk; menopause adds a further risk layer; vigilance and bone-health assessment are part of the picture. The cardio-protective effect of premenopausal oestrogen is lost at menopause; T1DM-related vascular risk compounds this. Hormone replacement therapy in T1DM is an emerging area; the review calls for T1DM-specific trials and recommends individualised decisions that weigh symptom burden, cardiovascular risk, and breast cancer risk.

The menopause-and-T1DM evidence base is the thinnest of the four stations in this part. Decisions are individual, the evidence is largely extrapolated from T2DM and general-population work, and the right shape of care is a conversation between you, your diabetes team, and a menopause-experienced clinician. Many of the women in the GNL community who have spent the last decade and a half supporting their own T1D children through diagnosis are now hitting their own perimenopause, and they have noticed that they have less guidance for this transition than they did for any of the previous ones. That is not a personal gap; it is a research gap. Bring the symptoms to your GP. Bring the glucose pattern to your diabetes team. Ask for joint care if the two conversations need to bridge.

The thread across all three parts

The cycle is signal where it is signal, the AID systems shift where the work goes without erasing it, and the wider hormonal life course meets T1D at four stations where the team configuration matters as much as the evidence. The work is yours; the science is what we bring to it; the conversation with your diabetes team and the wider clinicians who handle each station is the lever.

Evidence backbone, Part 3

Voice-first delivery; research-grade source layer. Tap a station for the citation detail.

The full per-source grade map and per-claim chain (overall Grade B, twenty-two per-source rows, thirteen per-claim rows, seven residual gaps) sits at gnl-grace/wiki/evidence-grades/menstrual-evidence.md. The concept page Grace’s RAG draws from is gnl-grace/wiki/concepts/menstrual-cycle-and-t1d.md.